Therapeutic strategies in childhood multiple sclerosis

Meeting Review: The management of multiple sclerosis in children: a European view

(2010) Angelo Ghezzi et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

(2009) M. Trojano et al.   ANNALS OF NEUROLOGY

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach

(2009) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

‘Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis’

(2009) Michael Karenfort et al.   DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY

‘Natalizumab in paediatric multiple sclerosis and service implication’

(2009) Richard E Appleton et al.   DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

(2009) F. Patti et al.   Multiple Sclerosis Journal

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

(2009) R Ellis et al.   Multiple Sclerosis Journal

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience

(2009) Angelo Ghezzi et al.   NEUROLOGICAL SCIENCES

Cyclophosphamide therapy in pediatric multiple sclerosis

(2009) N. Makhani et al.   NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Natalizumab Use in Pediatric Multiple Sclerosis

(2008) Peter Huppke et al.   ARCHIVES OF NEUROLOGY

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases

(2008) I. Elovaara et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: A comparative cohort study

(2008) Yann Mikaeloff et al.   EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY

Natalizumab treatment in pediatric multiple sclerosis: A case report

(2008) Giovanna Borriello et al.   EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

(2008) J Río et al.   Multiple Sclerosis Journal

Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients

(2008) Marco Capobianco et al.   NEUROLOGICAL SCIENCES

Predictive markers for response to interferon therapy in patients with multiple sclerosis

(2008) S. Malucchi et al.   NEUROLOGY

Cognitive and psychosocial features of childhood and juvenile MS

(2008) M. P. Amato et al.   NEUROLOGY

Vanishing MS T2-bright lesions before puberty: A distinct MRI phenotype?

(2008) D. Chabas et al.   NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE